RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Huntsville, AL · +125 more sites